Abstract Details

Title Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS®) Reduces Major Depressive Disorder (MDD) Symptom Severity

Topic General Neurology

Presentation(s) P10 - Poster Session 10 (5:00 PM-6:00 PM)

Poster/Presentation
Number 2-010

Objective Evaluate the efficacy of PrTMS as an effective adjunctive treatment for MDD. We hypothesize that PrTMS will significantly reduce MDD symptom severity.

Background Altered activity in the brain's default mode network (DMN), reflected in dysregulated alpha oscillations observed in EEG, is one hypothesis for the cause of some MDD subtypes. PrTMS utilizes spectral EEG guidance to iteratively optimize MDD symptom relief through low-power stimulation of multiple cortical areas. Adjustments of cortical treatment sites and stimulus frequency are guided by an algorithm identifying stimulation frequencies within the DMN alpha oscillatory band, targeting functional abnormalities.

Design/Methods A retrospective analysis was performed of data collected during PrTMS treatment for MDD. Patients received 20 PrTMS treatments and were categorized based on initial PHQ-9 scores (moderate 10-15; moderately severe 15-19; severe 20-27). Paired t-tests were utilized to determine whether there was statistically significant change from baseline. Demographic variables were assessed for differences using linear regression.

Results Mean age was 42±16 years (range: 18-101). Average treatment completion time was 77±57.7 days. 1673 patients (56.9% female; 43.1% male) completed 8365 PHQ-9 questionnaires. Of 713 with severe MDD, a significant decrease in score was observed from 23.9±2.8 to 14.7±7.9 (p<0.001). 68% exhibited improvement to moderately severe or better. Of 497 patients with moderately severe MDD, a significant decrease in score was observed from 17.0±1.5 to 11.0±6.1 (p<0.001). 71% exhibited improvement to moderate or better. Of 463 patients with moderate MDD, a significant decrease in score was observed from 11.9±1.4 to 8.1±5.5 (p<0.001). 87% exhibited improvement to mild and of those, 34% reached remission (PHQ-9<5). No effects of age or gender were observed.

Conclusions These data support the use of PrTMS in reducing MDD symptom severity and underscore its potential role in therapeutic outcomes. Questionnaires like PHQ-9 can introduce self-report bias, highlighting the need for prospective, controlled PrTMS studies to substantiate findings.

Authors/Disclosures
Jacob J. Shawwa PRESENTER	Mr. Shawwa has nothing to disclose.
Eugenio Reina	Mr. Reina has nothing to disclose.
Alan Ho, BA	Mr. Ho has received personal compensation for serving as an employee of Neurobit Innovations.
Caleigh S. Roach	Miss Roach has nothing to disclose.
Matthew A. Kis, BS	Mr. Kis has nothing to disclose.
Philip Harvey, PhD	Prof. Harvey has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alkermes. Prof. Harvey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer-Ingelheim. Prof. Harvey has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Karuna Therapeutics. Prof. Harvey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Minerva Neurosciences. Prof. Harvey has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Prof. Harvey has received intellectual property interests from a discovery or technology relating to health care. Prof. Harvey has received intellectual property interests from a discovery or technology relating to health care.
Carl I. Schulman, MD, PhD	Dr. Schulman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for PMI. Dr. Schulman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zoll. Dr. Schulman has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Williams Hart & Boundas, LLP . Dr. Schulman has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for MASE SEITZ BRIGGS. Dr. Schulman has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��